Mechanical circulatory support for patients with infarct-related cardiogenic shock: a state-of-the-art review
- PMID: 39819613
- DOI: 10.1136/heartjnl-2024-324883
Mechanical circulatory support for patients with infarct-related cardiogenic shock: a state-of-the-art review
Abstract
Acute myocardial infarction-related cardiogenic shock (AMI-CS) is a severe, life-threatening condition characterised by inadequate tissue perfusion due to the heart's inability to pump blood effectively. The pathophysiology of AMI-CS usually arises from the sudden loss of myocardial contractility, leading to a decrease in cardiac output and systemic hypoperfusion. In approximately 90% of AMI-CS cases, the left ventricle is the primary site of dysfunction.Despite early recognition and the implementation of strategies such as primary percutaneous coronary intervention, the mortality rate associated with AMI-CS remains alarmingly high, reflecting significant unmet clinical needs. A major challenge lies in identifying the optimal patient population for mechanical circulatory support (MCS) devices, as these interventions are costly and can lead to serious complications.This review provides a comprehensive overview of the pathophysiological mechanisms underlying AMI-CS, explores the current range of MCS devices available and offers an in-depth discussion on the balance of benefits and risks associated with these devices. By highlighting key evidence from recent studies, we aim to shed light on the clinical decision-making process and improve outcomes in this high-risk patient population.
Keywords: Heart-Assist Devices; Myocardial Infarction.
© Author(s) (or their employer(s)) 2025. No commercial re-use. See rights and permissions. Published by BMJ Group.
Conflict of interest statement
Competing interests: JEM received institutional research grants from Novo Nordisk Foundation and Abiomed; consulting fee from Boston Scientific; and speaker fees from Abbott, Abiomed and Boehringer Ingelheim. HT is the current president of the German Cardiac Society. UZ received institutional research grants from Pfizer, AstraZeneca and German Heart Foundation and speaker fees from Amgen, Bayer, BMS, Boehringer Ingelheim, Pfizer, Ferrer, Chiesi, Meril, Sanofi, Getinge, Fresenius and Zoll. AP received institutional funding from Getinge and Abiomed. CH received institutional research grants from the Novo Nordisk Foundation, Lundbeck Foundation and Danish Heart Foundation.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical